skip to main content

 

 


Donate

 

SINGULAR FOCUS IN OPHTHALMOLOGY
OUR 24/7/365

 

Vista Center Announces Live Your Best Life
in Partnership with Kodiak Sciences

Vista Center’s success in pivoting to deliver services in a virtual environment during the COVID-19 crisis has been possible only with help from generous friends! Eager to leverage community support, the Vista Center Board and staff recently reached a point of inflection, having thoughtfully considered rapidly changing client needs.

To that end, we are thrilled to announce our partnership with Premier Corporate Partner Kodiak Sciences, in the endorsement of the Vista Center Live Your Best Life campaign, a unique one-time opportunity for community stakeholders to lend support during a time of increasing need. https://www.vistacenterbestlife.org/

***********************

Kodiak Sciences Inc. is a clinical-stage company developing new medicines to treat chronic, high-prevalence retinal diseases. Kodiak is a patient-focused company and looks forward to deepening its roots in our shared local community. We are thrilled to support Vista Center in its mission and are honored to contribute to efforts that empower individuals who are blind or visually impaired.

Founded in 2009, we are focused on bringing new science to the design and manufacture of next generation retinal medicines to prevent and treat the leading causes of blindness globally. Our ABC Platform™ uses molecular engineering to merge the fields of antibody-based and chemistry-based therapies and is at the core of Kodiak's discovery engine. Kodiak's lead product candidate, KSI-301, is a novel anti-VEGF antibody biopolymer conjugate being developed for the treatment of retinal vascular diseases including age-related macular degeneration, a leading cause of blindness in elderly patients, and diabetic eye diseases, a leading cause of blindness in working-age patients. Kodiak has leveraged its ABC Platform to build a pipeline of product candidates in various stages of development including KSI-501, our bispecific anti-IL-6/VEGF biopolymer conjugate for the treatment of neovascular retinal diseases with an inflammatory component, and we are expanding our early research pipeline to include ABC Platform based triplet inhibitors for multifactorial retinal diseases such as dry AMD and glaucoma.

At Kodiak, we have been focused on improving patient lives since our inception as a company ten years ago. Our relationship with Vista Center is a continuation of our journey, one that connects us to the patients we serve. It is a privilege for Kodiak to engage with the Vista team and to volunteer in our shared community.

Image 1: Woman sitting on the floor with two children playing Image 1: Woman sitting on the floor with two children playing Image 3: Two adults playing jump rope outside with a child
TRAILBLAZING SCIENCE
"GO-TO" MEDICINES
SINGULAR FOCUS IN OPHTHALMOLOGY
OUR CREATIVE AND
THOUGHTFUL FOUNDATION
OUR CHALLENGE TO THE STATUS QUO
OUR 24/7/365